Market News Video
MNV MNV 10 Stocks Crossing Below Their 200 Day Moving Average
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Progenics Pharmaceuticals Becomes Oversold (PGNX)
Friday, January 8, 12:34 PM ET, by Market News Video Staff

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy ...

Short Interest Drops 21.4% For PGNX
Thursday, January 14, 4:06 PM ET, by Market News Video Staff

The most recent short interest data has been released by the NASDAQ for the 12/31/2015 ...

First Week of PGNX March 18th Options Trading
Monday, January 25, 11:21 AM ET, by Market News Video Staff

Investors in Progenics Pharmaceuticals, Inc. (PGNX) saw new options become available this week, for the ...

First Week of PGNX April 15th Options Trading
Thursday, February 25, 11:06 AM ET, by Market News Video Staff

Investors in Progenics Pharmaceuticals, Inc. (PGNX) saw new options begin trading this week, for the ...

Analysts Expect SMLF Will Reach $33
Friday, March 18, 7:37 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

  More articles:  1 2 3 4 5 6 7 next »

Commit To Buy Progenics Pharmaceuticals, Inc. At $4, Earn 29.1% Annualized

By Market News Video Staff, Wednesday, June 12, 2:36 PM ET
Play Video: How To Sell A PUT

If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Investors eyeing a purchase of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) stock, but tentative about paying the going market price of $4.70/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the November put at the $4 strike, which has a bid at the time of this writing of 50 cents. Collecting that bid as the premium represents a 12.5% return against the $4 commitment, or a 29.1% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

Selling a put does not give an investor access to PGNX's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $4 strike if doing so produced a better outcome than selling at the going market price. (Do options carry counterparty risk? This and six other common options myths debunked). So unless Progenics Pharmaceuticals, Inc. sees its shares decline 16.3% and the contract is exercised (resulting in a cost basis of $3.50 per share before broker commissions, subtracting the 50 cents from $4), the only upside to the put seller is from collecting that premium for the 29.1% annualized rate of return.

Below is a chart showing the trailing twelve month trading history for Progenics Pharmaceuticals, Inc., and highlighting in green where the $4 strike is located relative to that history:

The chart above, and the stock's historical volatility, can be a helpful guide in combination with fundamental analysis to judge whether selling the November put at the $4 strike for the 29.1% annualized rate of return represents good reward for the risks. We calculate the trailing twelve month volatility for Progenics Pharmaceuticals, Inc. (considering the last 249 trading day closing values as well as today's price of $4.70) to be 108%. For other put options contract ideas at the various different available expirations, visit the PGNX Stock Options page of

In mid-afternoon trading on Wednesday, the put volume among S&P 500 components was 1.26M contracts, with call volume at 1.62M, for a put:call ratio of 0.78 so far for the day, which is unusually high compared to the long-term median put:call ratio of .65. In other words, there are lots more put buyers out there in options trading so far today than would normally be seen, as compared to call buyers.

Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   November   Options   PGNX   Pharmaceuticals   Progenics   Stock   YieldBoost   among   annualized   benefit   buyers   call   cents   compared   contract   exercised   from   going   history   market   month   only   options   other   owning   premium   price   rate   ratio   represents   return   seller   selling   share   shares   stock   strike   that   there   this   today   trading   trailing   twelve   upside   volatility   where   which   with   would
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV MNV Chart Zero Stock Market Game Stock Market Definitions

Commit To Buy Progenics Pharmaceuticals, Inc. At $4, Earn 29.1% Annualized | Market News Video | Copyright © 2008 - 2017, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.